Making previously undruggable targets druggable and treating diseases for which no therapies exist
First written in FY2024. 3 of 5 entries say "Restated". Latest entry: 2026-05-18.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「Our mission is to use PepMetics technology to make targets previously considered "undruggable" druggable and treat diseases for which no therapies existed, relying on our proprietary drug discovery platform technology.」
The mission of making challenging drug targets druggable and treating diseases for which no therapies existed continues to be presented as a core management policy. - FY2025-H1RestatedAnnual report
「Using PepMetics technology to control intracellular signal transduction, the company aims to create therapeutics to cure intractable diseases such as cancer,」
The company has reaffirmed its direction of applying PepMetics technology to challenging drug targets and creating treatments for intractable diseases. - FY2024First statedAnnual report
「We are building a new drug discovery platform and developing new medicines with the aim of creating a new drug discovery paradigm by making targets previously considered undruggable druggable, and treating diseases for which no therapies existed.」
The company has set as its mission making challenging intracellular PPI targets amenable to drug development using PepMetics technology.